T. Kanto et al., DENSITY ANALYSIS OF HEPATITIS-C VIRUS PARTICLE-POPULATION IN THE CIRCULATION OF INFECTED HOSTS - IMPLICATIONS FOR VIRUS NEUTRALIZATION OR PERSISTENCE, Journal of hepatology, 22(4), 1995, pp. 440-448
Hepatitis C virus has a low buoyant density in sucrose, but high-densi
ty particles are often observed in hepatitis C virus infection. To inv
estigate the characteristics of circulating hepatitis C virus particle
s and their association with liver disease progression, we examined se
ra from two histologically normal hepatitis C virus carriers, 20 chron
ic hepatitis patients and five acute hepatitis C patients, The superna
tants obtained after immunoprecipitation with anti-immunoglobulins ant
ibody were subjected to sucrose equilibrium centrifugation, HCV-RNA po
sitive fractions separated after the treatments were further examined
for immunoprecipitation with anti-core hepatitis C virus antibody, We
separated hepatitis C virus particle populations according to the dens
ity difference on 35% sucrose with centrifugation, The proportions of
high and low density particles in hepatitis C virus populations were d
etermined by means of competitive reverse transcription and polymerase
chain reaction. Circulating hepatitis C virus particles in chronicall
y infected patients could be separated into two populations: those imm
unoglobulin-bound with high densities and -unbound with low densities,
Patients with severe liver inflammation had high-density hepatitis C
virus that did not precipitate with anti-immunoglobulins but with anti
-core hepatitis C virus antibodies, Thus, hepatitis C virus particle p
opulations consist of low density virions and high-density immune comp
lexes and/or nucleocapsids. Among the chronic hepatitis patients, the
dominant population shifted from low-density to high-density particles
with the progression of liver disease. In acute hepatitis patients, t
his density shift was observed with alanine aminotransferase normaliza
tions. Therefore, the major hepatitis C virus populations change from
virion to immune complex and/or nucleocapsid with the progression of l
iver disease or inflammation.